Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year agreement with the United States Department of Veterans Affairs (VA) National Precision Oncology Program (NPOP) designed to expand access to Tempus’ portfolio of next-generation sequencing offerings to support physicians in delivering personalized treatment approaches for their p...
Tempus, a leader in artificial intelligence and precision medicine, today announced abstracts accepted for presentation at the 2022 American Association for Cancer Research (AACR) Annual Meeting, which convenes in New Orleans from April 8th until April 13th, 2022. The presented research demonstrates how Tempus’ comprehensive genomic sequencing capabilities generate high-quali...
Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of Edge, an innovative platform that allows pathologists to access developing AI models intended to identify specimens with potentially actionable biomarkers using a single hematoxylin and eosin stain (H&E) slide. With access to over 50 petabytes of de-identified multi...
Tempus, a leader in artificial intelligence and precision medicine, today announced the acquisition of Highline Sciences, a specialized, full-service clinical contract research organization (CRO) focused on oncology. Highline Sciences manages and executes on early and late-stage clinical trials, applying a customized approach to each study. Highline’s capabilities and expertise will he...
Tempus, a leader in artificial intelligence and precision medicine, today announced the commencement of an open label phase II study, in collaboration with GlaxoSmithKline (GSK) to evaluate the efficacy and safety of ZEJULA (niraparib), a poly (ADP-ribose) polymerase (PARP) inhibitor used for patients with advanced or metastatic solid tumors and a germline...
Tempus, a leader in artificial intelligence and precision medicine, today announced six abstracts accepted for poster sessions at the 2021 San Antonio Breast Cancer Symposium (SABCS) taking place December 7 - 10. The presented findings highlight the unique insights that Tempus’ data and smart diagnostics generate to advance breast cancer research. ...
Tempus, a leader in artificial intelligence and precision medicine, today announced the expansion of its multi-year agreement with Janssen Research & Development, LLC (Janssen). The expanded scope is anchored in new AI-based work, in which Tempus will collaborate with a multidisciplinary team of data scientists at Janssen to enhance the discov...
Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) in which the two companies will work together to gather insights, discover novel drug targets, and aim to develop therapeutics for the broader oncology community. By combining the capa...
Tempus expands its existing provider EHR integrations to offer physicians seamless access to its genomic testing Tempus, a leader in artificial intelligence and precision medicine, announced that it is working with Epic to offer providers in-workflow integrations at scale. Since its founding, Tempus has strived to provide physicians seamles...
Tempus is integrating information from the Memorial Sloan Kettering Cancer Center’s OncoKB database and NCCN Guidelines into its clinical reports, providing physicians robust, well-vetted guidelines at their fingertips Tempus, a leader in artificial intelligence and precision medicine, today announced that it will incorporate data from both the Memor...